Patents by Inventor Edward M. Rudnic

Edward M. Rudnic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6663890
    Abstract: An antibiotic product, in particular metronidazole, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 16, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Publication number: 20030206951
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: December 20, 2002
    Publication date: November 6, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030203023
    Abstract: An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.
    Type: Application
    Filed: December 16, 2002
    Publication date: October 30, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Patent number: 6638532
    Abstract: An antibiotic product for delivering at least Tetracycline or Doxycycline that is comprised of three dosage forms with different release profiles with each of Tetracycline and Doxycycline being present in at least one of the dosage forms.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: October 28, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6632453
    Abstract: An antibiotic product for delivering at least Ciprofoxacin or Metronidazole that is comprised of three dosage forms with different release profiles with each of Ciprofoxacin and Metronidazole being present in at least one of the dosage forms.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: October 14, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6627222
    Abstract: An antibiotic product for delivering at least Amoxicillin or dicloxacillin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and dicloxacillin being present in at least one of the dosage forms.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: September 30, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbiter, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6623758
    Abstract: An antibiotic product for delivering at least cephalosporin or Metronidazole that is comprised of three dosage forms with different release profiles with each of cephalosporin and Metronidazole being present in at least one of the dosage forms.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: September 23, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6623757
    Abstract: An antibiotic product for delivering at least two different antibiotics that is comprised of three dosage forms with different release profiles with each antibiotic being present in at least one of the dosage forms.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: September 23, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6610328
    Abstract: An antibiotic product for delivering at least Amoxicillin or Clarithromycin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and Clarithromycin being present in at least one of the dosage forms.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: August 26, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Patent number: 6605300
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: August 12, 2003
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte M. McGuinness, Edward M. Rudnic
  • Publication number: 20030147953
    Abstract: An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-fungal from the product.
    Type: Application
    Filed: August 2, 2002
    Publication date: August 7, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030143273
    Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.
    Type: Application
    Filed: December 20, 2002
    Publication date: July 31, 2003
    Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
  • Publication number: 20030124188
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Application
    Filed: June 14, 2002
    Publication date: July 3, 2003
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte M. McGuinness, Edward M. Rudnic
  • Publication number: 20030104054
    Abstract: An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-neoplastic product being reached in less than about twelve hours after initial release of anti-neoplastic from the product.
    Type: Application
    Filed: August 2, 2002
    Publication date: June 5, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030104056
    Abstract: An anti-viral product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-viral product being reached in less than about twelve hours after initial release of anti-viral from the product.
    Type: Application
    Filed: August 2, 2002
    Publication date: June 5, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030104055
    Abstract: An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
    Type: Application
    Filed: August 2, 2002
    Publication date: June 5, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030104058
    Abstract: An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antineoplastic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: October 21, 2002
    Publication date: June 5, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030099706
    Abstract: An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: November 5, 2002
    Publication date: May 29, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030099707
    Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 29, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20030096007
    Abstract: An antibiotic product for delivering at least Amoxicillin or dicloxacillin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and dicloxacillin being present in at least one of the dosage forms.
    Type: Application
    Filed: March 7, 2002
    Publication date: May 22, 2003
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink